Bokf Na Reduces Stock Position in Bristol Myers Squibb Company $BMY

Bokf Na lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 10.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 236,607 shares of the biopharmaceutical company's stock after selling 27,973 shares during the period. Bokf Na's holdings in Bristol Myers Squibb were worth $12,763,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Novem Group boosted its position in Bristol Myers Squibb by 2.9% during the 4th quarter. Novem Group now owns 6,402 shares of the biopharmaceutical company's stock valued at $345,000 after buying an additional 183 shares during the period. Dominguez Wealth Management Solutions Inc. boosted its position in Bristol Myers Squibb by 0.8% during the 4th quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company's stock valued at $1,208,000 after buying an additional 185 shares during the period. McLean Asset Management Corp boosted its position in Bristol Myers Squibb by 3.1% during the 4th quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company's stock valued at $369,000 after buying an additional 192 shares during the period. Bath Savings Trust Co boosted its position in Bristol Myers Squibb by 2.3% during the 4th quarter. Bath Savings Trust Co now owns 8,743 shares of the biopharmaceutical company's stock valued at $472,000 after buying an additional 198 shares during the period. Finally, Traub Capital Management LLC boosted its position in Bristol Myers Squibb by 2.0% during the 4th quarter. Traub Capital Management LLC now owns 10,228 shares of the biopharmaceutical company's stock valued at $552,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Down 0.8%

Shares of NYSE:BMY opened at $56.94 on Wednesday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The firm has a market capitalization of $116.28 billion, a P/E ratio of 15.99, a P/E/G ratio of 0.16 and a beta of 0.26. The stock has a 50 day moving average price of $59.48 and a 200-day moving average price of $54.72. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the prior year, the company earned $1.80 EPS. The business's revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.29 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 70.79%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers launched a global "Won't Lose" media campaign ahead of the FIFA World Cup 2026 — a brand/awareness push that investors may view as supportive for long‑term patient/brand engagement. Bristol Myers Squibb Launches “Won't-Lose” Media Campaign
• Positive Sentiment: Slimming COVID tailwinds but continued product momentum across peers: Pfizer beat Q1 estimates and reaffirmed guidance, which supports healthcare-sector sentiment and can help lift large-cap pharma multiples. Pfizer Beats Earnings Estimates. The Drugmaker Is Finding Life After Covid.
• Neutral Sentiment: Zacks reports heightened investor attention in BMY—useful as a gauge of retail/analyst focus but not a direct fundamental change. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention
• Neutral Sentiment: Broader biotech restructuring: BioNTech is cutting ~22% of its workforce as it refocuses post‑COVID — a sector data point on how companies are adjusting, but not directly tied to BMY’s pipeline. BioNTech to Slash 22% of Workforce
• Negative Sentiment: Clinical setback for BMY’s franchise: Cytokinetics reported positive results for its myosin inhibitor in non-obstructive hypertrophic cardiomyopathy, a success where Bristol Myers’ Camzyos previously failed—this opens a large market opportunity for the rival and increases competitive risk to BMY’s heart‑failure strategy. Cytokinetics heart drug scores in closely watched trial
• Negative Sentiment: Analyst stance unchanged: Scotiabank maintained a Hold rating on BMY, signaling no immediate upgrade catalyst from that firm and limiting upside from analyst momentum. Scotiabank Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

Analysts Set New Price Targets

BMY has been the subject of several analyst reports. HSBC increased their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a research report on Tuesday, March 17th. Guggenheim reaffirmed a "buy" rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Bank of America dropped their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, April 9th. Wall Street Zen raised shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Sunday, April 19th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Bristol Myers Squibb in a research report on Friday. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $61.31.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.